IMGN

31.23 USD
0.00 (0.00%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

stock is down 0% since 30 days ago. The next earnings date is Aug 2, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 41.18% of the previous 34 July’s closed higher than June.

About

ImmunoGen, Inc. develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer.